These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 10561316)

  • 1. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
    Kantoff PW; Halabi S; Conaway M; Picus J; Kirshner J; Hars V; Trump D; Winer EP; Vogelzang NJ
    J Clin Oncol; 1999 Aug; 17(8):2506-13. PubMed ID: 10561316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
    Small EJ; Meyer M; Marshall ME; Reyno LM; Meyers FJ; Natale RB; Lenehan PF; Chen L; Slichenmyer WJ; Eisenberger M
    J Clin Oncol; 2000 Apr; 18(7):1440-50. PubMed ID: 10735891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
    Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
    Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.
    Levine EG; Halabi S; Roberts JD; Kaplan EB; Rago R; Atkins JN; Vogelzang NJ
    Cancer; 2002 Feb; 94(3):665-72. PubMed ID: 11857298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
    Tannock IF; Osoba D; Stockler MR; Ernst DS; Neville AJ; Moore MJ; Armitage GR; Wilson JJ; Venner PM; Coppin CM; Murphy KC
    J Clin Oncol; 1996 Jun; 14(6):1756-64. PubMed ID: 8656243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
    Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M
    J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
    Chi KN; Gleave ME; Klasa R; Murray N; Bryce C; Lopes de Menezes DE; D'Aloisio S; Tolcher AW
    Clin Cancer Res; 2001 Dec; 7(12):3920-7. PubMed ID: 11751483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
    Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
    J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
    BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.
    Savarese DM; Halabi S; Hars V; Akerley WL; Taplin ME; Godley PA; Hussain A; Small EJ; Vogelzang NJ
    J Clin Oncol; 2001 May; 19(9):2509-16. PubMed ID: 11331330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
    Berry WR
    Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone: new indication. More risky than beneficial in advanced prostate cancer.
    Prescrire Int; 2001 Aug; 10(54):110-2. PubMed ID: 11718179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
    Osoba D; Tannock IF; Ernst DS; Neville AJ
    J Clin Oncol; 1999 Jun; 17(6):1654-63. PubMed ID: 10561201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
    Van Poppel H
    Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.
    Wiseman LR; Spencer CM
    Drugs Aging; 1997 Jun; 10(6):473-85. PubMed ID: 9205852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group.
    Winquist E; Waldron T; Berry S; Ernst DS; Hotte S; Lukka H
    BMC Cancer; 2006 May; 6():112. PubMed ID: 16670021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.
    Cabrespine A; Guy L; Khenifar E; Curé H; Fleury J; Penault-Llorca F; Kwiatkowski F; Barthomeuf C; Chollet P; Bay JO
    Urology; 2006 Feb; 67(2):354-9. PubMed ID: 16442593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.